Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dermatrends has developed a transdermal nonsteroidal anti-inflammatory drug patch containing active ingredients such as meloxicam, which in oral form has been successfully used to treat crippling conditions such as osteoarthritis.
Subscribe to our email newsletter
The Dermatrends’ nonsteroidal anti-inflammatory drug (NSAID) patch has been tested extensively in vitro, indicating that drugs such as meloxicam can be delivered to match systemic blood level concentrations currently delivered orally.
A meloxicam patch smaller than a standard business card would be adequate to match the 15mg /day oral dosage and patch size would decrease proportionately for lower dosages.
Dermatrends’ patch completely bypasses the gastrointestinal (GI) tract, unlike many oral NSAIDs which can lead to discomfort and even more serious issues in the upper GI tract.
In addition, transdermal drug delivery allows for a constant delivery of drug rather than the peaks and valleys associated with oral formulations, helping to reduce dosage-dependant adverse GI reactions. Constant delivery also allows for steady relief of symptoms, allowing a single dosage to remain effective for a longer period of time.
“Our transdermal formulations should result in a safer, more effective pain relief product for millions of NSAID users,” said Ted Schwarzrock, Dermatrends chairman, president, and CEO.